Welcome. In this 15-minute discussion we cover Q3 Innovative Medicine Leadership Review and Required Safety Language. Everything we say comes from those documents.
Operational growth was 8.2% for the quarter.
Oncology and immunology led the growth. That figure is operational growth, not reported growth.
The core portfolio remains resilient.
Two areas need leadership attention: launch readiness and evidence generation.
Decision one: launch sequencing across priority markets.
Decision two: evidence generation timing.
Decision three: field force allocation.
Supply continuity is a risk in two markets.
Competitive entry is expected in the second half of 2027.
This content is for internal training use only and does not replace the approved prescribing information.
To recap the takeaways: growth was 8.2%, three decisions are open, and the required safety language applies.
Thanks for listening. Check the source references for every point.